Quick answer
Economic Survey 2025-26 places India 38th in the Global Innovation Index 2025, but GERD is only 0.64% of GDP: the next challenge is financing and commercialising research.
Innovation turns new knowledge into useful products, processes and enterprises; R&D is the systematic research effort that helps generate that knowledge. India’s improving innovation rankings and expanding start-up base coexist with low research intensity and limited business participation in R&D.
Concept diagram
Innovation and R&D: GII, Patents and Start-ups
A laboratory, patent document and start-up rocket connect invention to enterprise and commercial use.
- Patent counts and innovation outcomes are not interchangeable.
- Commercialisation also needs finance, skills and market demand.
Basics: inputs, rankings and intellectual property
GERD: the research input
- Gross domestic expenditure on R&D measures R&D performed within an economy. Research intensity = GERD ÷ GDP × 100; it is not the share of government spending devoted to science.
GII: a composite ranking
- WIPO’s Global Innovation Index assesses innovation inputs and outputs. A lower numerical rank is better; a rank is neither a percentage nor a direct measure of commercial success.
Patents: product and process inventions
- Product patents protect an eligible invention embodied in a product; process patents protect an eligible method. Novelty, inventive step and industrial applicability are central requirements, subject to statutory exclusions.
- An application requests protection; a grant follows examination. Trademarks distinguish commercial origin; industrial designs protect visual appearance rather than the underlying technical invention.
What the Survey reports: research and IP outputs
| Indicator | Survey finding | Interpretation |
|---|---|---|
| Scholarly publications | Global rank 7th in 2010 → 3rd currently | Research output, not an industrial production rank |
| GII 2025 | 38th; first among lower-middle-income economies and in Central and Southern Asia | Composite innovation performance |
| Global IP filings, 2024 | 4th in trademarks; 6th in patents; 7th in industrial designs | Filing ranks, not patent-grant ranks |
| FY20–FY25 IP trends | Patent applications nearly doubled; trademark registrations grew 1.5 times; designs registered rose 2.5 times | Charts VIII.21–VIII.22 and paragraph 8.44 use different IP measures |
| DPIIT-recognised start-ups | Approximately 500 at the 2016 launch → over 2 lakh by 25 November 2025 | A later cutoff than Chart VIII.23 |
Data chart
India’s improving Global Innovation Index rank
- India improved from 81st in 2015 to 38th in 2025.
- The unchanged rank of 40 in 2022–2023 does not imply an unchanged innovation score.
Source: Economic Survey 2025-26, Chart VIII.20 (World Intellectual Property Organization)
Show the data (Rank (lower is better))
| Period / item | GII rank |
|---|---|
| 2015 | 81 |
| 2020 | 48 |
| 2021 | 46 |
| 2022 | 40 |
| 2023 | 40 |
| 2024 | 39 |
| 2025 | 38 |
Data chart
DPIIT-recognised start-ups: cumulative expansion
- These are cumulative recognised entities, not annual new registrations or surviving profitable firms.
- The 1.97 lakh chart endpoint and the later over-2-lakh figure have different observation dates.
Source: Economic Survey 2025-26, Chart VIII.23 (DPIIT) · 2025 data are as on 31 October 2025; values reproduce the chart’s printed labels.
Show the data (Lakh start-ups)
| Period / item | Cumulative recognised start-ups |
|---|---|
| 2017 | 0.05 |
| 2018 | 0.14 |
| 2019 | 0.26 |
| 2020 | 0.41 |
| 2021 | 0.61 |
| 2022 | 0.88 |
| 2023 | 1.23 |
| 2024 | 1.57 |
| 2025* | 1.97 |
The financing constraint: research intensity and business participation
| Economy | GERD (% of GDP) | Business sector share of R&D expenditure (%) |
|---|---|---|
| India | 0.64 | 41 |
| United States | 3.48 | 75 |
| China | 2.43 | 77 |
| South Korea | 4.91 | 79 |
Boxes VIII.5–VIII.6: deployment versus research leadership
CSIR: take research beyond the laboratory
- Box VIII.5 highlights REJUPAVE and ECOFIX deployment in difficult terrain, bio-bitumen and steel-slag roads, and technology transfer for commercial manufacture of HANSA-3 NG.
- CSIR-NCL’s paracetamol process has been licensed commercially, with estimated manufacturing-cost reductions of 15–20%. These are examples of applied innovation, not a measured economy-wide productivity gain.
Critical technologies: capability is not deployment
- India is among the top five in 45 of 64 critical technologies, against four in 2003–2007. Box VIII.6 includes second place in biological manufacturing and third in post-quantum cryptography.
- ASPI’s rankings measure research output and relative scientific leadership; they do not establish industrial maturity, commercial deployment or production capability.
From research support to scalable industry
Coordinate research
ANRF, established under the ANRF Act, 2023, provides strategic direction, competitive funding opportunities and industry–academia–government collaboration pathways.
Finance technological risk
The RDI Fund has a ₹1 lakh crore six-year outlay and ₹20,000 crore allocated for FY26. It targets private high-tech R&D, advanced technology readiness, strategic technology acquisition and a Deep-Tech Fund of Funds.
Bridge research and markets
Quantum, AI, cyber-physical systems, semiconductor and green-hydrogen missions build domain capability. Startup India’s Fund of Funds, Seed Fund Scheme and Credit Guarantee Scheme address distinct financing needs.
Do not confuse innovation indicators
Statements examiners like to twist — learn the correct version.
The business sector spends 41% of India’s GDP on R&D.
Business accounts for 41% of total R&D expenditure; GERD itself is 0.64% of GDP. These have different denominators (Survey paragraphs 8.48–8.49; DST).
A patent application is an enforceable granted patent and proves commercial success.
Filing, grant and commercialisation are separate stages; none automatically guarantees the next.
The ₹1 lakh crore RDI outlay was all spent in FY26.
It is a six-year outlay; ₹20,000 crore is the FY26 allocation, not evidence of disbursement.
A top-five critical-technology rank proves domestic manufacturing self-sufficiency.
The ASPI rankings cited in Box VIII.6 concern research output, not industrial deployment.
Prelims focus
- Identify WIPO as the GII publisher; distinguish patents, trademarks and industrial designs.
- Remember GERD’s GDP denominator, ANRF Act 2023 and the difference between the RDI outlay and FY26 allocation.
Mains angle
- Explain why rising publications, patents and start-up recognition do not alone establish industrial technological leadership.
- Use low GERD and business participation to diagnose the financing gap; connect ANRF, RDI and CSIR technology transfer to research commercialisation.
Flip & recall
Answer in your head first, then tap the card to check.
Practice MCQs
Original Prelims-style questions with explanations.
0 / 3 correct · 3 left
Q1.GERD intensity is measured as:
Q2.Which statement about the RDI Fund is correct?
Q3.The ASPI critical-technology ranks cited in Box VIII.6 primarily indicate:
